Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: insights from the NEFIGAN trial-Reference-Cited by-同舟云学术

Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: insights from the NEFIGAN trial

Published:2024-02 Issue:2 Volume:105 Page:381-388
ISSN:0085-2538
Container-title:Kidney International
language:en
Short-container-title:Kidney International

Author:

Wimbury David,Muto Masahiro,Bhachu Jasraj S.,Scionti Katrin,Brown Jeremy,Molyneux Karen,Seikrit Claudia,Maixnerová Dita,Pérez-Alós Laura,Garred Peter,Floege Jürgen,Tesař Vladimír,Fellstrom Bengt,Coppo Rosanna^ORCID,Barratt Jonathan^ORCID

Publisher

Elsevier BV

Subject

Nephrology

Reference17 articles.

1. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial;Fellstrom;Lancet,2017

2. Intestinal fatty acid binding protein (I-FABP) as a possible biomarker of ileitis in patients with ulcerative colitis;Wiercinska-Drapalo;Regul Pept,2008

3. The intestinal barrier and current techniques for the assessment of gut permeability;Schoultz;Cells,2020

4. New insights into the pathogenesis of IgA nephropathy;Yeo;Pediatr Nephrol,2018

5. Primary IgA nephropathy: new insights into pathogenesis;Barratt;Semin Nephrol,2011

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathogenic Immunoglobulin A-Producing Cells in Immunoglobulin A Nephropathy;Journal of Clinical Medicine;2024-09-05

2. Therapy of IgA nephropathy: time for a paradigm change;Frontiers in Medicine;2024-08-15

3. Effect of tonsillectomy combined with steroid pulse therapy upon IgA nephropathy depending on proteinuria status at diagnosis: a nationwide multicenter cohort study in Japan;Clinical and Experimental Nephrology;2024-07-02

4. Insights on Nefecon®, a Targeted-Release Formulation of Budesonide and Its Selective Immunomodulatory Effects in Patients with IgA Nephropathy;Drug Design, Development and Therapy;2024-07

5. Can we effectively manage chronic kidney disease with a precision-based pharmacotherapy plan? Where are we?;Expert Opinion on Pharmacotherapy;2024-06-12